Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amyris Is Soaring Today

By Maxx Chatsko - Jun 1, 2020 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A bullish article is pushing shares higher, but investors need to remain grounded.

What happened

Shares of Amyris (AMRS 41.92%) soared as much as 20.9% today after an article on Seeking Alpha suggested the synthetic biology company could be the next Tesla. The bullish take -- the author's first article published on the platform -- pushed shares over the $4 mark for the first time since late 2019. 

On the one hand, what investor wouldn't want to own the next Tesla? Shares of the electric vehicle manufacturer and energy pioneer have jumped 3,570% since the initial public offering (IPO). On the other hand, there are many reasons suggesting Amyris is most definitely not the next Tesla. 

As of 11:53 a.m. EDT, the small-cap stock had settled to a 13.1% gain.

A woman with a shocked look on her face checking her phone.

Image source: Getty Images.

So what

The Seeking Alpha article made a handful of arguments as to why Amyris has the wind at its back, but investors that have followed the company's developments over the years might be a little more skeptical. After all, shares of Amyris have lost 98% of their value since the company's IPO.

For example, the article claims Amyris could grow annual revenue from a projected $220 million in 2020 to $600 million by 2022, which is something the company has previously told investors. That sounds great, but the reality is that Amyris has a long history of overpromising and undelivering

The article also suggests recent and upcoming capital raises will bolster the company's balance sheet. In reality, Amyris can fund itself only by selling shares and significantly diluting shareholders. The business ended March with $3 million in cash and reported a net loss of $86 million in the first quarter of 2020. It also failed to make debt and interest payments totaling $27.6 million in the month of April alone. More worrisome, it hasn't been expensing the cost of product revenue for its second most important source of revenue, which could lead to a significant charge or asset write-off in the coming quarters. 

Now what

Individual investors need to be careful not to let greed overtake their better judgment. Amyris turned in a solid first-quarter performance, but one quarter is not a trend and certainly not enough to overcome the steep financial headwinds facing the business. If the company issues stock to raise money, investors must realize most of it will be handed to creditors and used to keep the lights on, not invested in growth opportunities. Simply put, investors should stay away from the synthetic biology stock for now. It's not the next Tesla.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Tesla. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
AMRS
$3.25 (41.92%) $0.96
Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$883.07 (3.89%) $33.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.